Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404326 | 0.88 | LMNA (0.42) | ALDH1A1KCNA5CYP3A4CYP2C19FABP7 | |
| SCHEMBL19976426 | 0.86 | TSHR (0.45) | ALDH1A1CYP3A4CYP2C19MAPTTSHR | |
| SCHEMBL402948 | 0.82 | ALDH1A1 (0.41) | ALDH1A1KCNA5CYP3A4CYP2C19FABP7 | |
| SCHEMBL402676 | 0.82 | LMNA (0.34) | ALDH1A1KCNA5CYP3A4CYP2C19FABP7 | |
| SCHEMBL7564025 | 0.78 | BCHE (0.50) | — | |
| SCHEMBL7564019 | 0.78 | BCHE (0.50) | — | |
| SCHEMBL13044308 | 0.77 | TSHR (0.44) | ALDH1A1CYP3A4CYP2C19MAPTTSHR | |
| SCHEMBL13044610 | 0.77 | TSHR (0.44) | ALDH1A1CYP3A4CYP2C19MAPTTSHR | |
| SCHEMBL16018722 | 0.77 | PDE4D (0.42) | CYP2C19MAPT | |
| SCHEMBL14362880 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | ALDH1A1 371/4885KCNA5 1814/4885CYP3A4 538/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | ALDH1A1 364/4885KCNA5 1806/4885CYP3A4 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.